Refine
Has Fulltext
- yes (26)
Is part of the Bibliography
- yes (26)
Year of publication
- 2018 (26) (remove)
Document Type
- Journal article (18)
- Preprint (5)
- Conference Proceeding (3)
Language
- English (26)
Keywords
- Positronen-Emissions-Tomografie (15)
- PET (14)
- positron emission tomography (8)
- neuroendocrine tumor (5)
- SPECT (4)
- 18F-DCFPyL (3)
- 18F-FDG (3)
- DaTscan (3)
- PET/CT (3)
- RADS (3)
- SSTR (3)
- ageing (3)
- prostate cancer (3)
- theranostics (3)
- 11C-HED (2)
- 18F-LMI1195 (2)
- Ioflupane (2)
- PRRT (2)
- PSMA-PET (2)
- Parkinson (2)
- Parkinson Disease (2)
- Parkinson-Krankheit (2)
- Positron Emission Tomography (2)
- Prostate Cancer (2)
- Stammzelle (2)
- Virchow Node (2)
- [177Lu]-DOTATATE/-DOTATOC (2)
- [68Ga] (2)
- cardiomyocytes (2)
- fatty acid (2)
- hiPSC-CM (2)
- induced pluripotent stem cells (2)
- medullary thyroid carcinoma (2)
- molecular imaging (2)
- myocardial sympathetic innervation imaging (2)
- personalized medicine (2)
- personalized treatment (2)
- precision medicine (2)
- somatostatin receptor (2)
- stem cell therapy (2)
- tracer (2)
- tumor heterogeneity (2)
- tyrosine kinase inhibitor (2)
- vandetanib (2)
- 11C-Hydroxyephedrine (1)
- 11C-hydroxyephedrine (1)
- 123I-Ioflupane (1)
- 123I-mIBG (1)
- 123I-metaiodobenzylguanidine (1)
- 18F-FDS (1)
- 18F-flurpiridaz (1)
- 18FFBnTP (1)
- 2- deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- 68Ga-DOTATATE/-TOC (1)
- 99mTc-DTPA (1)
- Antidepressants (1)
- ECG (1)
- GI (1)
- Gastrointestinal (1)
- Glomerular filtration (1)
- HFmrEF (1)
- MDD (1)
- MPI (1)
- Medullärer Schilddrüsenkrebs (1)
- Myokarditis (1)
- Neuroendocrine (1)
- Neuroendocrine Tumor (1)
- Nierenfunktionsstörung (1)
- Oncology (1)
- PSMA (1)
- PSMA-RADS (1)
- PSMA-RADS-3A (1)
- PSMA-RADS-3B (1)
- PSMA-targeted PET (1)
- Pancreas (1)
- Parkinsonism (1)
- Parkinson’s disease (1)
- Positronenemissionstomografie (1)
- Radionuclide Therapy (1)
- SPECT/CT (1)
- SSTR-PET (1)
- Single-Photon-Emissions-Computertomographie (1)
- Standardisierung (1)
- TKI (1)
- ZDF rats (1)
- [68Ga]DOTATOC (1)
- \(^{18}\)F-FDG (1)
- \(^{18}\)F-fluorodeoxyglucose (1)
- antidepressant (1)
- cardiac sympathetic nerve system (1)
- cardiac sympathetic nervous system (1)
- coronary artery disease (1)
- depression (1)
- diabetes (1)
- diabetic cardiomyopathy (1)
- heart failure (1)
- heart failure with mid-range ejection fraction (1)
- hydroxyephedrine (1)
- inflammation (1)
- interobserver (1)
- interreader (1)
- major depressive disorder (1)
- moycardial sympathetic innervation (1)
- myocardial perfusion imaging (1)
- myocarditis (1)
- pancreas (1)
- peptide receptor radionuclide therapy (1)
- phaeochromocytoma (1)
- prostate-specific membrane antigen (1)
- prostate-specific membrane antigen (PSMA) (1)
- quantification (1)
- renal failure (1)
- reporting and data system (1)
- reporting and data systems (1)
- single photon emission computed tomography: sympathetic nerve (1)
- somatostatin receptor (SSTR) (1)
- standardization (1)
- storage vesicle turnover (1)
- sympathetic nervous system (1)
- unilateral ureteral obstruction (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (26) (remove)
Sonstige beteiligte Institutionen
- Johns Hopkins School of Medicine (13)
- Johns Hopkins University School of Medicine (5)
- Department of Biomedical Imaging, National Cerebral and Cardiovascular Research Center, Suita, Japan (2)
- Division of Medical Technology and Science, Department of Medical Physics and Engineering, Course of Health Science, Osaka University Graduate School of Medicine, Suita Japan (2)
- Institut for Molecular Biology and CMBI, Department of Genomics, Stem Cell Biology and Regenerative Medicine, Leopold-Franzens-University Innsbruck, Innsbruck, Austria (2)
- Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD, USA (2)
- Department of Nuclear Medicine, Kanazawa University (1)
- Johns Hopkins School of Medicine, Baltimore, MD, USA (1)
- Johns Hopkins University, Baltimore, MD, U.S. (1)
- National Cardiovascular and Cerebral Center, Suita, Japan (1)
EU-Project number / Contract (GA) number
- 701983 (26)
Introduction: Therapeutic options in advanced medullary thyroid carcinoma (MTC) have markedly improved since the introduction of tyrosine kinase inhibitors (TKI). We
aimed to assess the role of metabolic imaging using 2-deoxy-2-(\(^{18}\)F)fluoro-D-glucose (\(^{18}\)F-FDG) positron emission tomography/computed tomography (PET/CT) shortly before and 3 months after initiation of TKI treatment.
Methods: Eighteen patients with advanced and progressive MTC scheduled for vandetanib treatment underwent baseline \(^{18}\)F-FDG PET/CT prior to and 3 months after TKI treatment initiation. During follow-up, CT scans were performed every 3 months and analyzed according to Response Evaluation Criteria In Solid Tumors (RECIST). The predictive value for estimating progression-free (PFS) and overall survival (OS) was examined by investigating \(^{18}\)F-FDG mean/maximum standardized uptake values (SUVmean/max) of the metabolically most active lesion as well as by analyzing clinical parameters (tumor marker doubling times {calcitonin, carcinoembryonic antigen (CEA)}, prior therapies, RET (rearranged during transfection) mutational status, and disease type).
Results: Within a median follow-up of 5.2 years, 9 patients experienced disease progression after a median time interval of 2.1y whereas the remainder had ongoing disease control (n=5 partial response and n=4 stable disease). Eight of the 9 patients with progressive disease died from MTC after a median of 3.5y after TKI initiation.
Pre-therapeutic SUVmean >4.0 predicted a significantly shorter PFS (PFS: 1.9y vs. 5.2y; p=0.04). Furthermore, sustained high 18F-FDG uptake at 3 months with a SUVmean>2.8 tended to portend an unfavorable prognosis with a PFS of 1.9y (vs. 3.5y; p=0.3). Prolonged CEA doubling times were significantly correlated with longer PFS (r=0.7) and OS (r=0.76, p<0.01, respectively). None of the other clinical parameters had prognostic significance.
Conclusions: Pre-therapeutic \(^{18}\)F-FDG PET/CT holds prognostic information in patients with advanced MTC scheduled for treatment with the TKI vandetanib. Low tumor metabolism of SUVmean < 4.0 prior to treatment predicts longer progression-free survival.